Navigation Links
ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Date:5/14/2009

FREDERICK, Md., May 14 /PRNewswire/ -- ImQuest Bio and Arisyn jointly presented important new results on ATI-0810 (Formerly PG301029), a novel late stage inhibitor of hepatitis C virus (HCV) replication, at the 13th ISVHLD meeting held last week in Washington D.C. The presentation highlighted the ability of PG301029 to potently suppress the replication of HCV in vitro and defined its potential mechanism of antiviral action through the selection of a replicon resistant to the antiviral effects of the compound. Resistant HCV replicon sequences were selected in cell culture and resulted in mutations in the viral NS5A proximal to the NS5A-NS5B cleavage junction. The defined mutation would affect viral polyprotein processing at this site, or the interaction of NS5A, or the NS5A/5B polyprotein(s) with host cell factors involved in viral RNA replication, either of which presents a novel target for antiviral therapy. Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research, presented the new findings which also included gene profiling patterns in compound treated and untreated cells. The studies included ImQuest co-authors Lu Yang, MD and Robert W. Buckheit, Jr., Ph.D.

"The data presented indicate that PG301029 has a unique mechanism of action as an inhibitor of hepatitis C virus replication," said the study's Principal Investigator, Dr. Parsley. "The genetic analysis suggests that PG301029 functions through a novel antiviral target, and we are excited about the prospects for exploiting this target for the development of new and potent anti-HCV therapies."

The presentation represents a continuation of the research partnership between ImQuest and Arisyn for the development of Arisyn's portfolio of antiviral and anticancer products based on its platform technology involving targeting of RNA transcription. Funding for the study was obtained in part from a Small Business SBIR grant recently awarded to ImQuest by the NIH.

ImQuest BioSciences Inc., a privately held U.S. company located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

Arisyn Therapeutics Inc., a privately held virtual biotechnology company headquartered in Frederick, Maryland with a mission of identifying novel first in class inhibitors for infectious diseases and cancer and providing development resources for these agents through Phase 1 and 2 human clinical trials.

    For further information please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive VP and CSO
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
3. ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
6. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
(Date:6/23/2016)...  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member.  ... president and chief scientific officer, Mallinckrodt Pharmaceuticals, will ... Board of Directors. ... us in support of our efforts to conduct ...
Breaking Medicine Technology: